ID   JAK3_HUMAN              Reviewed;        1124 AA.
AC   P52333; Q13259; Q13260; Q13611; Q8N1E8; Q99699; Q9Y6S2;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2004, sequence version 2.
DT   12-OCT-2022, entry version 229.
DE   RecName: Full=Tyrosine-protein kinase JAK3 {ECO:0000305};
DE            EC=2.7.10.2;
DE   AltName: Full=Janus kinase 3;
DE            Short=JAK-3;
DE   AltName: Full=Leukocyte janus kinase;
DE            Short=L-JAK;
GN   Name=JAK3 {ECO:0000312|HGNC:HGNC:6193};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=8022790; DOI=10.1073/pnas.91.14.6374;
RA   Kawamura M., McVicar D.W., Johnston J.A., Blake T.B., Chen Y.-Q., Lal B.K.,
RA   Lloyd A.R., Kelvin D.J., Staples J.E., Ortaldo J.R., O'Shea J.J.;
RT   "Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase
RT   expressed in natural killer cells and activated leukocytes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:6374-6378(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ALTERNATIVE SPLICING (ISOFORM
RP   2).
RX   PubMed=7559633; DOI=10.1074/jbc.270.42.25028;
RA   Lai K.S., Jin Y., Graham D.K., Witthuhn B.A., Ihle J.N., Liu E.T.;
RT   "A kinase-deficient splice variant of the human JAK3 is expressed in
RT   hematopoietic and epithelial cancer cells.";
RL   J. Biol. Chem. 270:25028-25036(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8921370; DOI=10.1006/geno.1996.0520;
RA   Riedy M.C., Dutra A.S., Blake T.B., Modi W., Lal B.K., Davis J., Bosse A.,
RA   O'Shea J.J., Johnston J.A.;
RT   "Genomic sequence, organization, and chromosomal localization of human
RT   JAK3.";
RL   Genomics 37:57-61(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS THR-132 AND ILE-722.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 36-191.
RX   PubMed=8662778; DOI=10.1074/jbc.271.24.13976;
RA   Verbsky J.W., Bach E.A., Fang Y.F., Yang L., Randolph D.A., Fields L.E.;
RT   "Expression of Janus kinase 3 in human endothelial and other non-lymphoid
RT   and non-myeloid cells.";
RL   J. Biol. Chem. 271:13976-13980(1996).
RN   [9]
RP   FUNCTION IN IL2 SIGNALING PATHWAY.
RX   PubMed=8022485; DOI=10.1038/370151a0;
RA   Johnston J.A., Kawamura M., Kirken R.A., Chen Y.Q., Blake T.B., Shibuya K.,
RA   Ortaldo J.R., McVicar D.W., O'Shea J.J.;
RT   "Phosphorylation and activation of the Jak-3 Janus kinase in response to
RT   interleukin-2.";
RL   Nature 370:151-153(1994).
RN   [10]
RP   FUNCTION IN IL7 SIGNALING PATHWAY.
RX   PubMed=7662955;
RA   Sharfe N., Dadi H.K., Roifman C.M.;
RT   "JAK3 protein tyrosine kinase mediates interleukin-7-induced activation of
RT   phosphatidylinositol-3' kinase.";
RL   Blood 86:2077-2085(1995).
RN   [11]
RP   TISSUE SPECIFICITY.
RX   PubMed=7535338; DOI=10.1084/jem.181.4.1425;
RA   Musso T., Johnston J.A., Linnekin D., Varesio L., Rowe T.K., O'Shea J.J.,
RA   McVicar D.W.;
RT   "Regulation of JAK3 expression in human monocytes: phosphorylation in
RT   response to interleukins 2, 4, and 7.";
RL   J. Exp. Med. 181:1425-1431(1995).
RN   [12]
RP   INTERACTION WITH STAM2.
RC   TISSUE=Fetal brain;
RX   PubMed=10899310; DOI=10.1016/s0014-5793(00)01760-9;
RA   Endo K., Takeshita T., Kasai H., Sasaki Y., Tanaka N., Asao H., Kikuchi K.,
RA   Yamada M., Chenb M., O'Shea J.J., Sugamura K.;
RT   "STAM2, a new member of the STAM family, binding to the Janus kinases.";
RL   FEBS Lett. 477:55-61(2000).
RN   [13]
RP   INTERACTION WITH SHB.
RX   PubMed=12200137; DOI=10.1016/s0006-291x(02)02016-8;
RA   Lindholm C.K.;
RT   "IL-2 receptor signaling through the Shb adapter protein in T and NK
RT   cells.";
RL   Biochem. Biophys. Res. Commun. 296:929-936(2002).
RN   [14]
RP   FUNCTION IN CYTOKINE SIGNALING, PHOSPHORYLATION, AND DEPHOSPHORYLATION AT
RP   TYR-980 AND TYR-981 BY PTPN2.
RX   PubMed=11909529; DOI=10.1016/s0960-9822(02)00697-8;
RA   Simoncic P.D., Lee-Loy A., Barber D.L., Tremblay M.L., McGlade C.J.;
RT   "The T cell protein tyrosine phosphatase is a negative regulator of janus
RT   family kinases 1 and 3.";
RL   Curr. Biol. 12:446-453(2002).
RN   [15]
RP   DOMAIN.
RX   PubMed=12351625; DOI=10.1074/jbc.m205156200;
RA   Saharinen P., Silvennoinen O.;
RT   "The pseudokinase domain is required for suppression of basal activity of
RT   Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of
RT   signal transduction.";
RL   J. Biol. Chem. 277:47954-47963(2002).
RN   [16]
RP   PHOSPHORYLATION AT TYR-785, AND MUTAGENESIS OF TYR-785.
RX   PubMed=15121872; DOI=10.1128/mcb.24.10.4557-4570.2004;
RA   Kurzer J.H., Argetsinger L.S., Zhou Y.J., Kouadio J.L., O'Shea J.J.,
RA   Carter-Su C.;
RT   "Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation
RT   of JAK2 by SH2-B beta.";
RL   Mol. Cell. Biol. 24:4557-4570(2004).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [18]
RP   PHOSPHORYLATION AT TYR-904 AND TYR-939, AND MUTAGENESIS OF LYS-855; TYR-904
RP   AND TYR-939.
RX   PubMed=18250158; DOI=10.1128/mcb.01789-07;
RA   Cheng H., Ross J.A., Frost J.A., Kirken R.A.;
RT   "Phosphorylation of human Jak3 at tyrosines 904 and 939 positively
RT   regulates its activity.";
RL   Mol. Cell. Biol. 28:2271-2282(2008).
RN   [19]
RP   REVIEW ON FUNCTION.
RX   PubMed=19290934; DOI=10.1111/j.1600-065x.2008.00754.x;
RA   Ghoreschi K., Laurence A., O'Shea J.J.;
RT   "Janus kinases in immune cell signaling.";
RL   Immunol. Rev. 228:273-287(2009).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [22]
RP   FUNCTION IN IL15 SIGNALING PATHWAY.
RX   PubMed=20440074; DOI=10.1172/jci41344;
RA   Malamut G., El Machhour R., Montcuquet N., Martin-Lanneree S.,
RA   Dusanter-Fourt I., Verkarre V., Mention J.J., Rahmi G., Kiyono H.,
RA   Butz E.A., Brousse N., Cellier C., Cerf-Bensussan N., Meresse B.;
RT   "IL-15 triggers an antiapoptotic pathway in human intraepithelial
RT   lymphocytes that is a potential new target in celiac disease-associated
RT   inflammation and lymphomagenesis.";
RL   J. Clin. Invest. 120:2131-2143(2010).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 814-1103 IN COMPLEX WITH
RP   STAUROSPORINE ANALOG AFN941, AND PHOSPHORYLATION AT TYR-980 AND TYR-981.
RX   PubMed=15831699; DOI=10.1182/blood-2005-02-0707;
RA   Boggon T.J., Li Y., Manley P.W., Eck M.J.;
RT   "Crystal structure of the Jak3 kinase domain in complex with a
RT   staurosporine analog.";
RL   Blood 106:996-1002(2005).
RN   [24]
RP   VARIANT T(-)B(+)NK(-) SCID CYS-100.
RX   PubMed=7659163; DOI=10.1038/377065a0;
RA   Macchi P., Villa A., Giliani S., Sacco M.G., Frattini A., Porta F.,
RA   Ugazio A.G., Johnston J.A., Candotti F., O'Shea J.J., Vezzoni P.,
RA   Notarangelo L.D.;
RT   "Mutations of Jak-3 gene in patients with autosomal severe combined immune
RT   deficiency (SCID).";
RL   Nature 377:65-68(1995).
RN   [25]
RP   VARIANTS T(-)B(+)NK(-) SCID GLY-481; 586-LEU--MET-592 DEL AND ARG-759.
RX   PubMed=9354668;
RA   Candotti F., Oakes S.A., Johnston J.A., Giliani S., Schumacher R.F.,
RA   Mella P., Fiorini M., Ugazio A.G., Badolato R., Notarangelo L.D., Bozzi F.,
RA   Macchi P., Strina D., Vezzoni P., Blaese R.M., O'Shea J.J., Villa A.;
RT   "Structural and functional basis for JAK3-deficient severe combined
RT   immunodeficiency.";
RL   Blood 90:3996-4003(1997).
RN   [26]
RP   VARIANT T(-)B(+)NK(-) SCID TRP-582.
RX   PubMed=9753072; DOI=10.1111/j.1365-2141.1998.tb08990.x;
RA   Bozzi F., Lefranc G., Villa A., Badolato R., Schumacher R.F., Khalil G.,
RA   Loiselet J., Bresciani S., O'Shea J.J., Vezzoni P., Notarangelo L.D.,
RA   Candotti F.;
RT   "Molecular and biochemical characterization of JAK3 deficiency in a patient
RT   with severe combined immunodeficiency over 20 years after bone marrow
RT   transplantation: implications for treatment.";
RL   Br. J. Haematol. 102:1363-1366(1998).
RN   [27]
RP   VARIANTS T(-)B(+)NK(-) SCID ARG-151 AND SER-910, AND VARIANT ILE-722.
RX   PubMed=10982185; DOI=10.1007/s004390051012;
RA   Schumacher R.F., Mella P., Badolato R., Fiorini M., Savoldi G., Giliani S.,
RA   Villa A., Candotti F., Tampalini A., O'Shea J.J., Notarangelo L.D.;
RT   "Complete genomic organization of the human JAK3 gene and mutation analysis
RT   in severe combined immunodeficiency by single-strand conformation
RT   polymorphism.";
RL   Hum. Genet. 106:73-79(2000).
RN   [28]
RP   VARIANTS T(-)B(+)NK(-) SCID ALA-58 DEL; GLU-169 AND SER-589, AND VARIANT
RP   ILE-722.
RX   PubMed=14615376; DOI=10.1182/blood-2003-06-2104;
RA   Roberts J.L., Lengi A., Brown S.M., Chen M., Zhou Y.-J., O'Shea J.J.,
RA   Buckley R.H.;
RT   "Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular
RT   analyses of 10 patients and outcomes of stem cell transplantation.";
RL   Blood 103:2009-2018(2004).
RN   [29]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-12; HIS-40; THR-132; ARG-151; VAL-521;
RP   PRO-527; PHE-688 AND ILE-722.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor tyrosine kinase involved in various processes
CC       such as cell growth, development, or differentiation. Mediates
CC       essential signaling events in both innate and adaptive immunity and
CC       plays a crucial role in hematopoiesis during T-cells development. In
CC       the cytoplasm, plays a pivotal role in signal transduction via its
CC       association with type I receptors sharing the common subunit gamma such
CC       as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to
CC       cell surface receptors, phosphorylates specific tyrosine residues on
CC       the cytoplasmic tails of the receptor, creating docking sites for STATs
CC       proteins. Subsequently, phosphorylates the STATs proteins once they are
CC       recruited to the receptor. Phosphorylated STATs then form homodimer or
CC       heterodimers and translocate to the nucleus to activate gene
CC       transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3
CC       molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits
CC       inducing the tyrosine phosphorylation of both receptor subunits on
CC       their cytoplasmic domain. Then, STAT5A and STAT5B are recruited,
CC       phosphorylated and activated by JAK1 and JAK3. Once activated,
CC       dimerized STAT5 translocates to the nucleus and promotes the
CC       transcription of specific target genes in a cytokine-specific fashion.
CC       {ECO:0000269|PubMed:11909529, ECO:0000269|PubMed:20440074,
CC       ECO:0000269|PubMed:7662955, ECO:0000269|PubMed:8022485}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- SUBUNIT: Interacts with STAM2 and MYO18A (By similarity). Interacts
CC       with SHB. {ECO:0000250, ECO:0000269|PubMed:10899310,
CC       ECO:0000269|PubMed:12200137, ECO:0000269|PubMed:15831699}.
CC   -!- INTERACTION:
CC       P52333; Q07666: KHDRBS1; NbExp=2; IntAct=EBI-518246, EBI-1364;
CC       P52333; Q9UNF1: MAGED2; NbExp=4; IntAct=EBI-518246, EBI-725832;
CC       P52333; P55209: NAP1L1; NbExp=4; IntAct=EBI-518246, EBI-356392;
CC   -!- SUBCELLULAR LOCATION: Endomembrane system {ECO:0000250}; Peripheral
CC       membrane protein {ECO:0000250}. Cytoplasm {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=2; Synonyms=JAK3S, Spleen-JAK3;
CC         IsoId=P52333-1; Sequence=Displayed;
CC       Name=1; Synonyms=JAK3B, Breast-JAK3;
CC         IsoId=P52333-2; Sequence=VSP_004989;
CC       Name=3;
CC         IsoId=P52333-4; Sequence=VSP_054165, VSP_054166;
CC   -!- TISSUE SPECIFICITY: In NK cells and an NK-like cell line but not in
CC       resting T-cells or in other tissues. The S-form is more commonly seen
CC       in hematopoietic lines, whereas the B-form is detected in cells both of
CC       hematopoietic and epithelial origins. {ECO:0000269|PubMed:7535338}.
CC   -!- DOMAIN: Possesses two phosphotransferase domains. The second one
CC       probably contains the catalytic domain (By similarity), while the
CC       presence of slight differences suggest a different role for domain 1.
CC       {ECO:0000250, ECO:0000269|PubMed:12351625}.
CC   -!- PTM: Tyrosine phosphorylated in response to IL-2 and IL-4.
CC       Dephosphorylation of Tyr-980 and Tyr-981 by PTPN2 negatively regulates
CC       cytokine-mediated signaling (Probable). {ECO:0000305|PubMed:11909529,
CC       ECO:0000305|PubMed:15121872, ECO:0000305|PubMed:15831699,
CC       ECO:0000305|PubMed:18250158}.
CC   -!- DISEASE: Severe combined immunodeficiency autosomal recessive T-cell-
CC       negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-) SCID)
CC       [MIM:600802]: A form of severe combined immunodeficiency (SCID), a
CC       genetically and clinically heterogeneous group of rare congenital
CC       disorders characterized by impairment of both humoral and cell-mediated
CC       immunity, leukopenia, and low or absent antibody levels. Patients
CC       present in infancy recurrent, persistent infections by opportunistic
CC       organisms. The common characteristic of all types of SCID is absence of
CC       T-cell-mediated cellular immunity due to a defect in T-cell
CC       development. {ECO:0000269|PubMed:10982185, ECO:0000269|PubMed:14615376,
CC       ECO:0000269|PubMed:7659163, ECO:0000269|PubMed:9354668,
CC       ECO:0000269|PubMed:9753072}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 1]: May be inactive as it lacks some part of
CC       the kinase domain. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. JAK subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC50227.1; Type=Miscellaneous discrepancy; Note=Wrong choice of CDS. Was erroneously described as an isoform JAK3M while it is a fragmentary mRNA of INSL3.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/JAK3ID41032ch19p13.html";
CC   -!- WEB RESOURCE: Name=JAK3base; Note=JAK3 mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/JAK3base/";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/jak3/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U09607; AAA19626.1; -; mRNA.
DR   EMBL; U31601; AAC50226.1; -; mRNA.
DR   EMBL; U31602; AAC50227.1; ALT_SEQ; mRNA.
DR   EMBL; U70065; AAC50950.1; -; Genomic_DNA.
DR   EMBL; AF513860; AAM44860.1; -; Genomic_DNA.
DR   EMBL; AC007201; AAD22741.1; -; Genomic_DNA.
DR   EMBL; CH471106; EAW84639.1; -; Genomic_DNA.
DR   EMBL; BC028068; AAH28068.1; -; mRNA.
DR   EMBL; U57096; AAC50542.1; -; mRNA.
DR   CCDS; CCDS12366.1; -. [P52333-1]
DR   PIR; A55747; A55747.
DR   RefSeq; NP_000206.2; NM_000215.3. [P52333-1]
DR   PDB; 1YVJ; X-ray; 2.55 A; A=814-1103.
DR   PDB; 3LXK; X-ray; 2.00 A; A=806-1124.
DR   PDB; 3LXL; X-ray; 1.74 A; A=806-1124.
DR   PDB; 3PJC; X-ray; 2.20 A; A=812-1124.
DR   PDB; 3ZC6; X-ray; 2.42 A; A/B/C/D=813-1100.
DR   PDB; 3ZEP; X-ray; 2.35 A; A/B/C/D=813-1047, A/B/C/D=813-1100.
DR   PDB; 4HVD; X-ray; 1.85 A; A=811-1124.
DR   PDB; 4HVG; X-ray; 2.75 A; A=811-1124.
DR   PDB; 4HVH; X-ray; 2.30 A; A=811-1124.
DR   PDB; 4HVI; X-ray; 2.40 A; A=811-1124.
DR   PDB; 4I6Q; X-ray; 1.85 A; A=811-1124.
DR   PDB; 4QPS; X-ray; 1.80 A; A/C=811-1103.
DR   PDB; 4QT1; X-ray; 2.40 A; A=811-1124.
DR   PDB; 4RIO; X-ray; 2.69 A; A=810-1100.
DR   PDB; 4V0G; X-ray; 3.00 A; A/B=816-1098.
DR   PDB; 4Z16; X-ray; 2.90 A; A/B/C/D=811-1124.
DR   PDB; 5LWM; X-ray; 1.55 A; A=812-1103.
DR   PDB; 5LWN; X-ray; 1.60 A; A=812-1103.
DR   PDB; 5TOZ; X-ray; 1.98 A; A=812-1124.
DR   PDB; 5TTS; X-ray; 2.34 A; A=812-1124.
DR   PDB; 5TTU; X-ray; 1.72 A; A=812-1124.
DR   PDB; 5TTV; X-ray; 1.93 A; A=812-1124.
DR   PDB; 5VO6; X-ray; 2.65 A; A=812-1100.
DR   PDB; 5W86; X-ray; 2.61 A; A/B/C/D=814-1100.
DR   PDB; 5WFJ; X-ray; 2.48 A; A=810-1100.
DR   PDB; 6AAK; X-ray; 2.67 A; A/B/C/D=814-1100.
DR   PDB; 6DA4; X-ray; 2.90 A; A=812-1124.
DR   PDB; 6DB3; X-ray; 1.97 A; A=812-1124.
DR   PDB; 6DB4; X-ray; 1.66 A; A=812-1124.
DR   PDB; 6DUD; X-ray; 1.66 A; A=812-1124.
DR   PDB; 6GL9; X-ray; 1.70 A; A/B=812-1103.
DR   PDB; 6GLA; X-ray; 1.92 A; A/B=812-1103.
DR   PDB; 6GLB; X-ray; 2.00 A; A/B=812-1103.
DR   PDB; 6HZV; X-ray; 2.46 A; A/B/C/D=815-1099.
DR   PDB; 6NY4; X-ray; 2.33 A; A=810-1100.
DR   PDB; 7APF; X-ray; 1.95 A; A/B=812-1103.
DR   PDB; 7APG; X-ray; 2.40 A; A/B/C/D=812-1103.
DR   PDB; 7C3N; X-ray; 1.98 A; A=812-1124.
DR   PDB; 7Q6H; X-ray; 1.75 A; AAA=806-1124.
DR   PDBsum; 1YVJ; -.
DR   PDBsum; 3LXK; -.
DR   PDBsum; 3LXL; -.
DR   PDBsum; 3PJC; -.
DR   PDBsum; 3ZC6; -.
DR   PDBsum; 3ZEP; -.
DR   PDBsum; 4HVD; -.
DR   PDBsum; 4HVG; -.
DR   PDBsum; 4HVH; -.
DR   PDBsum; 4HVI; -.
DR   PDBsum; 4I6Q; -.
DR   PDBsum; 4QPS; -.
DR   PDBsum; 4QT1; -.
DR   PDBsum; 4RIO; -.
DR   PDBsum; 4V0G; -.
DR   PDBsum; 4Z16; -.
DR   PDBsum; 5LWM; -.
DR   PDBsum; 5LWN; -.
DR   PDBsum; 5TOZ; -.
DR   PDBsum; 5TTS; -.
DR   PDBsum; 5TTU; -.
DR   PDBsum; 5TTV; -.
DR   PDBsum; 5VO6; -.
DR   PDBsum; 5W86; -.
DR   PDBsum; 5WFJ; -.
DR   PDBsum; 6AAK; -.
DR   PDBsum; 6DA4; -.
DR   PDBsum; 6DB3; -.
DR   PDBsum; 6DB4; -.
DR   PDBsum; 6DUD; -.
DR   PDBsum; 6GL9; -.
DR   PDBsum; 6GLA; -.
DR   PDBsum; 6GLB; -.
DR   PDBsum; 6HZV; -.
DR   PDBsum; 6NY4; -.
DR   PDBsum; 7APF; -.
DR   PDBsum; 7APG; -.
DR   PDBsum; 7C3N; -.
DR   PDBsum; 7Q6H; -.
DR   AlphaFoldDB; P52333; -.
DR   SMR; P52333; -.
DR   BioGRID; 109921; 87.
DR   DIP; DIP-274N; -.
DR   IntAct; P52333; 86.
DR   MINT; P52333; -.
DR   STRING; 9606.ENSP00000391676; -.
DR   BindingDB; P52333; -.
DR   ChEMBL; CHEMBL2148; -.
DR   DrugBank; DB04716; 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one.
DR   DrugBank; DB11817; Baricitinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB06321; R-348.
DR   DrugBank; DB08877; Ruxolitinib.
DR   DrugBank; DB08895; Tofacitinib.
DR   DrugBank; DB15035; Zanubrutinib.
DR   DrugCentral; P52333; -.
DR   GuidetoPHARMACOLOGY; 2049; -.
DR   iPTMnet; P52333; -.
DR   PhosphoSitePlus; P52333; -.
DR   BioMuta; JAK3; -.
DR   DMDM; 50403745; -.
DR   jPOST; P52333; -.
DR   MassIVE; P52333; -.
DR   MaxQB; P52333; -.
DR   PaxDb; P52333; -.
DR   PeptideAtlas; P52333; -.
DR   PRIDE; P52333; -.
DR   ProteomicsDB; 56482; -. [P52333-1]
DR   ProteomicsDB; 56483; -. [P52333-2]
DR   ProteomicsDB; 71591; -.
DR   Antibodypedia; 35352; 486 antibodies from 35 providers.
DR   DNASU; 3718; -.
DR   Ensembl; ENST00000458235.7; ENSP00000391676.1; ENSG00000105639.20. [P52333-1]
DR   Ensembl; ENST00000527670.5; ENSP00000432511.1; ENSG00000105639.20. [P52333-1]
DR   Ensembl; ENST00000534444.1; ENSP00000436421.1; ENSG00000105639.20. [P52333-2]
DR   GeneID; 3718; -.
DR   KEGG; hsa:3718; -.
DR   MANE-Select; ENST00000458235.7; ENSP00000391676.1; NM_000215.4; NP_000206.2.
DR   UCSC; uc002nhn.5; human. [P52333-1]
DR   CTD; 3718; -.
DR   DisGeNET; 3718; -.
DR   GeneCards; JAK3; -.
DR   HGNC; HGNC:6193; JAK3.
DR   HPA; ENSG00000105639; Tissue enhanced (lymphoid).
DR   MalaCards; JAK3; -.
DR   MIM; 600173; gene.
DR   MIM; 600802; phenotype.
DR   neXtProt; NX_P52333; -.
DR   OpenTargets; ENSG00000105639; -.
DR   Orphanet; 35078; T-B+ severe combined immunodeficiency due to JAK3 deficiency.
DR   PharmGKB; PA29990; -.
DR   VEuPathDB; HostDB:ENSG00000105639; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   GeneTree; ENSGT00940000161827; -.
DR   HOGENOM; CLU_008155_1_0_1; -.
DR   InParanoid; P52333; -.
DR   OMA; TEDLKCW; -.
DR   OrthoDB; 58906at2759; -.
DR   PhylomeDB; P52333; -.
DR   TreeFam; TF327041; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; P52333; -.
DR   Reactome; R-HSA-1266695; Interleukin-7 signaling.
DR   Reactome; R-HSA-201556; Signaling by ALK.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-8854691; Interleukin-20 family signaling.
DR   Reactome; R-HSA-8983432; Interleukin-15 signaling.
DR   Reactome; R-HSA-8985947; Interleukin-9 signaling.
DR   Reactome; R-HSA-9020558; Interleukin-2 signaling.
DR   Reactome; R-HSA-9020958; Interleukin-21 signaling.
DR   Reactome; R-HSA-912526; Interleukin receptor SHC signaling.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   SignaLink; P52333; -.
DR   SIGNOR; P52333; -.
DR   BioGRID-ORCS; 3718; 14 hits in 1108 CRISPR screens.
DR   EvolutionaryTrace; P52333; -.
DR   GeneWiki; Janus_kinase_3; -.
DR   GenomeRNAi; 3718; -.
DR   Pharos; P52333; Tclin.
DR   PRO; PR:P52333; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P52333; protein.
DR   Bgee; ENSG00000105639; Expressed in granulocyte and 148 other tissues.
DR   ExpressionAtlas; P52333; baseline and differential.
DR   Genevisible; P52333; HS.
DR   GO; GO:0005856; C:cytoskeleton; IEA:InterPro.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005768; C:endosome; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005126; F:cytokine receptor binding; IBA:GO_Central.
DR   GO; GO:0005131; F:growth hormone receptor binding; IBA:GO_Central.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; ISS:BHF-UCL.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0030183; P:B cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0007167; P:enzyme-linked receptor protein signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0030218; P:erythrocyte differentiation; IBA:GO_Central.
DR   GO; GO:0060397; P:growth hormone receptor signaling pathway via JAK-STAT; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0038110; P:interleukin-2-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0035771; P:interleukin-4-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; ISS:BHF-UCL.
DR   GO; GO:0002731; P:negative regulation of dendritic cell cytokine production; ISS:BHF-UCL.
DR   GO; GO:0045221; P:negative regulation of FasL production; ISS:BHF-UCL.
DR   GO; GO:0032693; P:negative regulation of interleukin-10 production; ISS:BHF-UCL.
DR   GO; GO:0032695; P:negative regulation of interleukin-12 production; ISS:BHF-UCL.
DR   GO; GO:0050868; P:negative regulation of T cell activation; ISS:BHF-UCL.
DR   GO; GO:0045626; P:negative regulation of T-helper 1 cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0070244; P:negative regulation of thymocyte apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0042104; P:positive regulation of activated T cell proliferation; IEA:Ensembl.
DR   GO; GO:0051928; P:positive regulation of calcium ion transport; IEA:Ensembl.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IEA:Ensembl.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0007259; P:receptor signaling pathway via JAK-STAT; IBA:GO_Central.
DR   GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0046425; P:regulation of receptor signaling pathway via JAK-STAT; TAS:UniProtKB.
DR   GO; GO:0070232; P:regulation of T cell apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0070672; P:response to interleukin-15; TAS:BHF-UCL.
DR   GO; GO:0070669; P:response to interleukin-2; TAS:BHF-UCL.
DR   GO; GO:0070670; P:response to interleukin-4; IDA:BHF-UCL.
DR   GO; GO:0071104; P:response to interleukin-9; TAS:BHF-UCL.
DR   GO; GO:0043029; P:T cell homeostasis; ISS:BHF-UCL.
DR   GO; GO:0007260; P:tyrosine phosphorylation of STAT protein; IBA:GO_Central.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR019749; Band_41_domain.
DR   InterPro; IPR000299; FERM_domain.
DR   InterPro; IPR041155; FERM_F1.
DR   InterPro; IPR041046; FERM_F2.
DR   InterPro; IPR041381; JAK1-3/TYK2_PHL_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016251; Tyr_kinase_non-rcpt_Jak/Tyk2.
DR   InterPro; IPR020775; Tyr_kinase_non-rcpt_Jak3.
DR   Pfam; PF18379; FERM_F1; 1.
DR   Pfam; PF18377; FERM_F2; 1.
DR   Pfam; PF17887; Jak1_Phl; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 2.
DR   PIRSF; PIRSF000636; TyrPK_Jak; 1.
DR   PRINTS; PR01823; JANUSKINASE.
DR   PRINTS; PR01826; JANUSKINASE3.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00295; B41; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00219; TyrKc; 2.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50057; FERM_3; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 2.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing; ATP-binding;
KW   Cytoplasm; Disease variant; Immunity; Innate immunity; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome; Repeat; SCID;
KW   SH2 domain; Transferase; Tyrosine-protein kinase.
FT   CHAIN           1..1124
FT                   /note="Tyrosine-protein kinase JAK3"
FT                   /id="PRO_0000088115"
FT   DOMAIN          24..356
FT                   /note="FERM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00084"
FT   DOMAIN          375..475
FT                   /note="SH2; atypical"
FT   DOMAIN          521..781
FT                   /note="Protein kinase 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          822..1111
FT                   /note="Protein kinase 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..223
FT                   /note="Interaction with cytokine/interferon/growth hormone
FT                   receptors"
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        949
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         828..836
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         855
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         17
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62137"
FT   MOD_RES         785
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15121872"
FT   MOD_RES         904
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:18250158"
FT   MOD_RES         939
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:18250158"
FT   MOD_RES         980
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15831699"
FT   MOD_RES         981
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15831699"
FT   VAR_SEQ         597..619
FT                   /note="TMVQEFVHLGAIDMYLRKRGHLV -> ESPPPTHPTPASPKSRLFFPPLF
FT                   (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_054165"
FT   VAR_SEQ         620..1124
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_054166"
FT   VAR_SEQ         1071..1124
FT                   /note="HELMKLCWAPSPQDRPSFSALGPQLDMLWSGSRGCETHAFTAHPEGKHHSLS
FT                   FS -> SAAGLASVSQSVDWAGVSGKPAGA (in isoform 1)"
FT                   /evidence="ECO:0000303|PubMed:7559633"
FT                   /id="VSP_004989"
FT   VARIANT         12
FT                   /note="P -> L (in dbSNP:rs56061056)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041722"
FT   VARIANT         40
FT                   /note="R -> H (in dbSNP:rs56384680)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041723"
FT   VARIANT         58
FT                   /note="Missing (in T(-)B(+)NK(-) SCID)"
FT                   /evidence="ECO:0000269|PubMed:14615376"
FT                   /id="VAR_019337"
FT   VARIANT         100
FT                   /note="Y -> C (in T(-)B(+)NK(-) SCID; dbSNP:rs137852624)"
FT                   /evidence="ECO:0000269|PubMed:7659163"
FT                   /id="VAR_006284"
FT   VARIANT         132
FT                   /note="P -> T (in dbSNP:rs3212723)"
FT                   /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.4"
FT                   /id="VAR_019336"
FT   VARIANT         151
FT                   /note="P -> R (in T(-)B(+)NK(-) SCID; likely benign
FT                   variant; dbSNP:rs55778349)"
FT                   /evidence="ECO:0000269|PubMed:10982185,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_010492"
FT   VARIANT         169
FT                   /note="D -> E (in T(-)B(+)NK(-) SCID; dbSNP:rs147181709)"
FT                   /evidence="ECO:0000269|PubMed:14615376"
FT                   /id="VAR_019338"
FT   VARIANT         481
FT                   /note="E -> G (in T(-)B(+)NK(-) SCID)"
FT                   /evidence="ECO:0000269|PubMed:9354668"
FT                   /id="VAR_010493"
FT   VARIANT         521
FT                   /note="L -> V (in dbSNP:rs55666418)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041724"
FT   VARIANT         527
FT                   /note="L -> P (in a gastric adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041725"
FT   VARIANT         582
FT                   /note="R -> W (in T(-)B(+)NK(-) SCID; dbSNP:rs193922361)"
FT                   /evidence="ECO:0000269|PubMed:9753072"
FT                   /id="VAR_010494"
FT   VARIANT         586..592
FT                   /note="Missing (in T(-)B(+)NK(-) SCID; lack of
FT                   phosphorylation in response to cytokine stimulation)"
FT                   /evidence="ECO:0000269|PubMed:9354668"
FT                   /id="VAR_010495"
FT   VARIANT         589
FT                   /note="G -> S (in T(-)B(+)NK(-) SCID; dbSNP:rs886039394)"
FT                   /evidence="ECO:0000269|PubMed:14615376"
FT                   /id="VAR_019339"
FT   VARIANT         688
FT                   /note="I -> F (in dbSNP:rs35785705)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041726"
FT   VARIANT         722
FT                   /note="V -> I (in dbSNP:rs3213409)"
FT                   /evidence="ECO:0000269|PubMed:10982185,
FT                   ECO:0000269|PubMed:14615376, ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|Ref.4"
FT                   /id="VAR_010496"
FT   VARIANT         759
FT                   /note="C -> R (in T(-)B(+)NK(-) SCID; constitutive
FT                   phosphorylation)"
FT                   /evidence="ECO:0000269|PubMed:9354668"
FT                   /id="VAR_010497"
FT   VARIANT         910
FT                   /note="L -> S (in T(-)B(+)NK(-) SCID)"
FT                   /evidence="ECO:0000269|PubMed:10982185"
FT                   /id="VAR_010498"
FT   MUTAGEN         785
FT                   /note="Y->F: Strong decrease of JAK3 phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:15121872"
FT   MUTAGEN         855
FT                   /note="K->A: More than 90% loss of STAT5a activation."
FT                   /evidence="ECO:0000269|PubMed:18250158"
FT   MUTAGEN         904
FT                   /note="Y->F: About 40% loss of STAT5a activation."
FT                   /evidence="ECO:0000269|PubMed:18250158"
FT   MUTAGEN         939
FT                   /note="Y->F: About 80% loss of STAT5a activation."
FT                   /evidence="ECO:0000269|PubMed:18250158"
FT   CONFLICT        34
FT                   /note="G -> A (in Ref. 1; AAA19626)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        45
FT                   /note="F -> S (in Ref. 3; AAC50950)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        103
FT                   /note="R -> RS (in Ref. 3; AAC50950)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        147
FT                   /note="Missing (in Ref. 8; AAC50542)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        187
FT                   /note="T -> A (in Ref. 8; AAC50542)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        212
FT                   /note="R -> A (in Ref. 1; AAA19626 and 3; AAC50950)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        222
FT                   /note="R -> P (in Ref. 1; AAA19626 and 3; AAC50950)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        271
FT                   /note="L -> F (in Ref. 3; AAC50950)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        287
FT                   /note="Missing (in Ref. 3; AAC50950)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        610
FT                   /note="M -> I (in Ref. 2; AAC50226)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        845..846
FT                   /note="GD -> AH (in Ref. 1; AAA19626)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        895..897
FT                   /note="RQS -> EPE (in Ref. 3; AAC50950)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        896..897
FT                   /note="QS -> PE (in Ref. 1; AAA19626)"
FT                   /evidence="ECO:0000305"
FT   STRAND          816..818
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   HELIX           819..821
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   STRAND          822..830
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   STRAND          832..841
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   STRAND          845..847
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   STRAND          849..859
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   HELIX           862..877
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   STRAND          886..891
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   STRAND          893..896
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   STRAND          898..903
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   HELIX           910..917
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   HELIX           918..920
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   HELIX           923..942
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   HELIX           952..954
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   STRAND          955..959
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   STRAND          962..965
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   HELIX           968..970
FT                   /evidence="ECO:0007829|PDB:3LXL"
FT   STRAND          979..982
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   HELIX           991..993
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   HELIX           996..1001
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   STRAND          1003..1005
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   HELIX           1006..1021
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   TURN            1022..1024
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   HELIX           1026..1028
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   HELIX           1030..1037
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   STRAND          1042..1044
FT                   /evidence="ECO:0007829|PDB:4QPS"
FT   HELIX           1046..1055
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   HELIX           1068..1077
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   HELIX           1082..1084
FT                   /evidence="ECO:0007829|PDB:5LWM"
FT   HELIX           1088..1102
FT                   /evidence="ECO:0007829|PDB:5LWM"
SQ   SEQUENCE   1124 AA;  125099 MW;  895D8563439B2B7C CRC64;
     MAPPSEETPL IPQRSCSLLS TEAGALHVLL PARGPGPPQR LSFSFGDHLA EDLCVQAAKA
     SGILPVYHSL FALATEDLSC WFPPSHIFSV EDASTQVLLY RIRFYFPNWF GLEKCHRFGL
     RKDLASAILD LPVLEHLFAQ HRSDLVSGRL PVGLSLKEQG ECLSLAVLDL ARMAREQAQR
     PGELLKTVSY KACLPPSLRD LIQGLSFVTR RRIRRTVRRA LRRVAACQAD RHSLMAKYIM
     DLERLDPAGA AETFHVGLPG ALGGHDGLGL LRVAGDGGIA WTQGEQEVLQ PFCDFPEIVD
     ISIKQAPRVG PAGEHRLVTV TRTDNQILEA EFPGLPEALS FVALVDGYFR LTTDSQHFFC
     KEVAPPRLLE EVAEQCHGPI TLDFAINKLK TGGSRPGSYV LRRSPQDFDS FLLTVCVQNP
     LGPDYKGCLI RRSPTGTFLL VGLSRPHSSL RELLATCWDG GLHVDGVAVT LTSCCIPRPK
     EKSNLIVVQR GHSPPTSSLV QPQSQYQLSQ MTFHKIPADS LEWHENLGHG SFTKIYRGCR
     HEVVDGEARK TEVLLKVMDA KHKNCMESFL EAASLMSQVS YRHLVLLHGV CMAGDSTMVQ
     EFVHLGAIDM YLRKRGHLVP ASWKLQVVKQ LAYALNYLED KGLPHGNVSA RKVLLAREGA
     DGSPPFIKLS DPGVSPAVLS LEMLTDRIPW VAPECLREAQ TLSLEADKWG FGATVWEVFS
     GVTMPISALD PAKKLQFYED RQQLPAPKWT ELALLIQQCM AYEPVQRPSF RAVIRDLNSL
     ISSDYELLSD PTPGALAPRD GLWNGAQLYA CQDPTIFEER HLKYISQLGK GNFGSVELCR
     YDPLGDNTGA LVAVKQLQHS GPDQQRDFQR EIQILKALHS DFIVKYRGVS YGPGRQSLRL
     VMEYLPSGCL RDFLQRHRAR LDASRLLLYS SQICKGMEYL GSRRCVHRDL AARNILVESE
     AHVKIADFGL AKLLPLDKDY YVVREPGQSP IFWYAPESLS DNIFSRQSDV WSFGVVLYEL
     FTYCDKSCSP SAEFLRMMGC ERDVPALCRL LELLEEGQRL PAPPACPAEV HELMKLCWAP
     SPQDRPSFSA LGPQLDMLWS GSRGCETHAF TAHPEGKHHS LSFS
//
